Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$27.18M$27.18M+5.4% vs Q3 2016 Net Income$6.89M$6.89M−23.1% vs Q3 2016 EPS Diluted$0.46$0.46−22.0% vs Q3 2016 Gross Profit$20,928,000+0.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$12,100,000+6.9% Free Cash Flowderived$9,511,000+10.9% Margins · derivedGross margin77.0%−3.6 pt vs Q3 2016
Operating margin37.8%−15.3 pt vs Q3 2016
Net margin25.3%−9.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Oct 27, 2017 · 27 d after period end